-transparent.png){kind=logo}
A phase II study of metoprine in low dose and in high dose with citrovorum rescue was conducted in patients with non-small-cell lung carcinoma. There were no responses observed in the 36 patients studied, yielding a predicted true response rate of less than 9%. Thrombocytopenia was the dose-limiting toxicity of the low-dose regimen; there was also one episode of leukopenia and sepsis in this group. Although citrovorum rescue obviated hematologic toxicity in the high-dose regimen, mild to moderate neurological toxicity occurred at this dose. Metoprine does not appear to be a useful agent in non-small-cell lung carcinoma when used in the dose schedule employed in this study.
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
January 1981,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
February 1985,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
April 1979,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
August 1979,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
January 1981,
Cancer clinical trials,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
November 1983,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
January 1981,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
January 1988,
Medical and pediatric oncology,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
January 1980,
Cancer treatment reports,
G R Lynch, and
R J Gralla, and
D P Kelsen, and
E S Casper, and
M B Stoopler, and
R B Golbey
June 1986,
Japanese journal of clinical oncology,
